Skip to main content
OpenTrials
Completed

NCT Number: NCT01346072

Pilot Study of Using Copeptin to Predict Response to Tolvaptan

This pilot study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin. The study will enroll stable outpatients with CHF with reduced LVEF (≤45) selected by targeting upper and lower quartile copeptin levels at screening (10 each). The treatment phase of the study will be a prospective, single-arm, open label protocol. All patients will receive active therapy consisting of a single oral dose of 30 mg of tolvaptan with body weight, fluid intake, and urine output monitored in a research unit for 24 hours.

For analysis of study endpoints, patients in the single intervention arm will be stratified by a prospectively determined cut-point of copeptin level into two groups (≥10 versus <10 pmol/L). The copeptin level used for the two group stratification will be the blinded copeptin value obtained at baseline from the hospital phase prior to administration of tolvaptan.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States

About this study

The study screening strategy will be designed to enroll an enriched patient population by identifying patients at the high or low end of the spectrum of copeptin levels for outpatients with stable heart failure. This will be accomplished by blinded review of copeptin levels obtained during screening.

The primary endpoints for analysis will be 24 hour urine output and the change in body weight over 24 hours during the inpatient stay.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients with a history of chronic symptomatic heart failure, defined as dyspnea on exertion or edema, due to cardiac dysfunction, of at least one month's duration
  • Left ventricular ejection fraction ≤ 45% as documented by quantitative assessment by an accepted imaging technique within one year of screening
  • Meet baseline copeptin criteria for entry
  • Currently taking a diuretic (with diuretic defined as any loop or thiazide diuretic or aldosterone antagonist at any dose)

Exclusion criteria

  • Current New York Heart Association Functional Class IV heart failure
  • Patients who are felt to be volume depleted based on clinical examination or need to reduce diuretic administration
  • Presence of clinical contraindications to tolvaptan
  • Episode of acute myocardial infarction or acute coronary syndrome within the past 3 months
  • Cardiovascular surgical procedure within the past 4 weeks
  • CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid cardiomyopathy.
  • History of primary significant liver disease or acute hepatic failure, as defined by the investigator.
  • Chronic uncontrolled diabetes mellitus as determined by the investigator.
  • Supine systolic arterial blood pressure < 90 mmHg at screening
  • Serum creatinine > 3.5 mg/dL at screening
  • Serum potassium > 5.5 mEq/L or < 3.5 mEq/L at screening
  • Subjects currently treated with hemofiltration or dialysis

j. Subjects judged by the investigator to be unable to maintain accurate intake and output during their hospitalization related to medical or other problems

Treatment and study plan

Tolvaptan

Drug

oral, 30 mg, single dose, one time administration

Other names: Samsca

Primary outcomes

  1. Urine Output

    Time frame: 24 hours

    Total urine output for 24 hours following tolvaptan administration

  2. Body Weight

    Time frame: Change over 24 hours

    Change in body weight from baseline to 24 hours after tolvaptan administration

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • Otsuka America Pharmaceutical

Registry information

Official study title

Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
May 2, 2011
Registry last updated
May 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.